61396-67-6

Usage

Uses

Used in Chemical Synthesis:
1,2-Propanediol, 3-(2-nitrophenoxy)is used as an intermediate chemical in the synthesis of more complex compounds. Its unique structure allows it to participate in various chemical reactions, making it a valuable component in the production of advanced materials and pharmaceuticals.
Used in Pharmaceutical Industry:
1,2-Propanediol, 3-(2-nitrophenoxy)is used as a building block for the development of new pharmaceutical compounds. Its specific chemical properties enable it to be incorporated into drug molecules, potentially leading to the creation of novel therapeutic agents with improved efficacy and safety profiles.
Used in Material Science:
1,2-Propanediol, 3-(2-nitrophenoxy)is used as a component in the development of new materials with unique properties. Its incorporation into material formulations can lead to the creation of advanced materials with enhanced performance characteristics, such as improved strength, flexibility, or thermal stability.
Used in Research and Development:
1,2-Propanediol, 3-(2-nitrophenoxy)is used as a research compound in academic and industrial laboratories. Its complex structure and potential reactivity make it an interesting subject for studies aimed at understanding its chemical behavior and exploring its potential applications in various fields.

Upstream product

• 824-38-4 potassium 2-nitrophenoxide 
• 96-24-2 3-monochloro-1,2-propanediol 
• 88-75-5 2-hydroxynitrobenzene 
• 21407-49-8 2-nitrophenyl glycidyl ether 
• 123-91-1 1,4-dioxane 

Downstream Products

• 63905-25-9 2-hydroxy-3-(2-aminophenoxy)propanol 
• 1186240-98-1 C₁₅H₂₅NO₅Si 
• 80491-49-2 2-(2,3-dihydroxypropoxy)benzene aminium chloride 
• 1186241-04-2 2-[[4-[(4-Methoxy-2,6-dimethyl-phenyl)sulfonyl]-3,4-dihydro-2H-[1,4]benzoxazin-3-yl]-methoxy]-acetic acid 
• 1186241-00-8 C₁₅H₂₅NO₂Si 
• 1186240-99-2 C₁₅H₂₃NO₅Si 
• 1186241-06-4 C₁₆H₁₆ClNO₄S 
• 1186241-02-0 C₁₈H₂₁NO₅S 
• 1186241-07-5 C₂₂H₂₆ClNO₆S 
• 1186241-05-3 C₂₂H₃₀ClNO₄SSi 
• 1186241-03-1 C₂₄H₃₁NO₇S 
• 1186241-01-9 C₂₄H₃₅NO₅SSi 
• 1186240-87-8 N-((1-(2-((4-(4-methoxy-2,6-dimethylphenylsulfonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-3-yl)methoxy)acetyl)-4-(4-methylpiperazin-1-yl)piperidin-4-yl)methyl)isonicotinamide 
• 1187964-52-8 C₂₂H₂₈F₃NO₄SSi 

Relevant academic research and scientific papers

Synthesis and aminopeptidase n inhibiting activity of 3-(nitrophenoxymethyl)-[1,3,2]dioxaborolan-2-OLS and their open analogues

Aminopeptidase N (APN) represents a class of zinc metallopeptidases with broad substrate specifity. This enzyme is involved in control of angioneogenesis in cancer and microvascular conditions. It also serves as a superficial cellular receptor that enables attachment of some viruses including coronaviruses to the host cell. APN takes part also in metabolism of some important neuropeptides. That is why APN can be a promising therapeutic target and compounds which influence its activity interesting potential drugs. Here, synthesis of compounds which in most contain 3-phenoxypropan-1,2 diol moiety and evaluation of their inhibition activity against APN is described. 4-[1-, 2- and 3-(Nitrophenoxymethyl)]-[1,3,2]dioxaborolan-2-ols are novel compounds which have never been previously reported in the literature. 3-(Aminophenoxy)propyl-1,2-diols revealed greater activity than both 3-(nitrophenoxy)propyl-1,2-diols and 3-(nitrophenoxymethyl)-[1,3,2]dioxaborolan-2-ols. A QSAR study revealed a linear correlation between lipophilicity and inhibition activity.

A rare case of facial selectivity inversion for Sharpless asymmetric dihydroxylation in a series of structurally homogeneous substrates: Synthesis of non-racemic 3-(nitrophenoxy)-propane-1,2-diols

Asymmetric dihydroxylation of mono nitrophenyl allyl ethers leads to the corresponding non-racemic 3-(nitrophenoxy)-propane-1,2-diols 1a-c. As this takes place, regardless of the reagent used (AD-mix-α or AD-mix-β), the configuration of the predominant enantiomer for the para- and meta-nitrosubstituted products is opposite to the configuration of the ortho-nitrophenyl derivative. A correlation between the melting points and vibrational spectra of the racemic and enantiopure diols 1a-c allowed us to establish that all of the chiral substances investigated formed stable racemic compounds in the solid phase.

Substituted Sulfonamide Compounds

Substituted sulfonamide compounds corresponding to the formula I: processes for the preparation thereof, pharmaceutical composition containing these compounds and the use of substituted sulfonamide compounds for the preparation of pharmaceutical compositions.

Substituted Sulfonamide Compounds

Substituted sulfonamide compounds corresponding to formula I: a process for their preparation, pharmaceutical compositions comprising such compounds, and the use of such substituted sulfonamide compounds in pharmaceutical compositions for the treatment of pain or other disorders or diseases that are mediated at least in part by B1R receptors.

SUBSTITUTED SULFONAMIDE DERIVATIVES

The invention relates to substituted sulfonamide derivatives, processes for the preparation thereof, medicaments containing these compounds and the use of substituted sulfonamide derivatives for the preparation of medicaments.

SUBSTITUTED SULFONAMIDE COMPOUNDS

Substituted sulfonamide compounds corresponding to formula I processes for the preparation thereof, pharmaceutical compositions containing these compounds, and the use of such substituted sulfonamide compounds in pharmaceutical compositions for the treatment and/or inhibition of pain and other conditions at least partly mediated by the bradykinin 1 receptor

SUBSTITUTED SULFONAMIDE DERIVATIVES

The invention relates to substituted sulfonamide derivatives, processes for the preparation thereof, medicaments containing these compounds and the use of substituted sulfonamide derivatives for the preparation of medicaments.

1-(2-Ar-4-aryloxymethyl-1,3-dioxolan-2-ylmethyl)imidazoles

1-(2-Ar-4-aryloxymethyl-1,3-dioxolan-2-ylmethyl)imidazoles, useful as antifungal and antibacterial agents.